For high-risk patients who receive chemoradiation therapy for head and neck cancer, frequent follow-up appointments conducted by advance practice nurses (APN) in a clinical outpatient setting allowed for more intensive symptom management. This program resulted in fewer post-treatment emergency room visits and hospital admissions compared to historical outcomes, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.

syngo.via RT Image Suite

Magnetom RT Pro Edition

In October, Siemens Healthcare debuted a host of imaging systems that enable RT professionals to go further in the direction of personalized therapy.

The American College of Radiology (ACR) spoke out against the U.S. Preventive Services Task Force’s (USPSTF) exclusion of computed tomography (CT) colonography from its most recent list of recommended exams for colorectal cancer screening, saying the decision could be a significant blow to efforts to raise colorectal cancer screening rates.

image-guided IMRT, IG-IMRT, bowel side effects, cervical cancer patients, ASTRO 2015

October 20, 2015 — For cervical cancer patients undergoing postsurgical radiation therapy, image-guided intensity-modulated radiation therapy (IG-IMRT) resulted in a 14 percent reduction in moderate-to-severe bowel side effects when compared to conventional three-dimensional conformal radiation therapy (3-D CRT).

Siemens’ PETNET Solutions Inc., a wholly owned subsidiary of Siemens Healthcare, will formulate the VPAC1 molecular biomarker 64Cu TP-3805 exclusively for clinical trials for the biopharmaceutical firm NuView Life Sciences Inc., of Park City, Utah.

Immunotherapy combined with palliative radiation therapy (RT) for a subset of patients with metastatic melanoma reduces the growth and spread of the cancer, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.

Orfit Industries introduced and demonstrated its HP Pro Solution, an innovative, comprehensive and versatile immobilization system for proton therapy, at the American Society for Radiation Oncology (ASTRO) 57th annual meeting. The technology, designed for brain, head and neck treatments, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now